Predictive factors for acute and late urinary toxicity after permanent interstitial brachytherapy in Japanese patients

Ryuta Tanimoto, Kensuke Bekku, Norihisa Katayama, Yasuyuki Kobayashi, Shin Ebara, Motoo Araki, Mitsuhiro Takemoto, Hiroyuki Yanai, Yasutomo Nasu, Hiromi Kumon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To describe the frequency of and to determine predictive factors associated with Radiation Therapy Oncology Group urinary toxicity in prostate brachytherapy patients. Methods: From January 2004 to April 2011, 466 consecutive Japanese patients underwent permanent iodine-125-seed brachytherapy (median follow up 48 months). International Prostate Symptom Score and Radiation Therapy Oncology Group toxicity data were prospectively collected. Prostate volume, International Prostate Symptom Score before and after brachytherapy, and postimplant analysis were examined for an association with urinary toxicity, defined as Radiation Therapy Oncology Group urinary toxicity of Grade1 or higher. Logistic regression analysis was used to examine the factors associated with urinary toxicity. Results: The rate of Radiation Therapy Oncology Group urinary toxicity grade1 or higher at 1, 6, 12, 24, 36 and 48 months was 67%, 40%, 21%, 31%, 27% and 28%, respectively. Grade2 or higher urinary toxicity was less than 1% at each time-point. International Prostate Symptom Score was highest at 3 months and returned to normal 12 months after brachytherapy. On univariate analysis, patients with a larger prostate size, greater baseline International Prostate Symptom Score, higher prostate V100, higher prostate V150, higher prostate D90 and a greater number of seeds had more acute urinary toxicities at 1 month and 12 months after brachytherapy. On multivariate analysis, significant predictors for urinary toxicity at 1 month and 12 months were a greater baseline International Prostate Symptom Score and prostate V100. Conclusions: Most urinary symptoms are tolerated and resolved within 12 months after prostate brachytherapy. Acute and late urinary toxicity after brachytherapy is strongly related to the baseline International Prostate Symptom Score and prostate V100.

Original languageEnglish
Pages (from-to)812-817
Number of pages6
JournalInternational Journal of Urology
Volume20
Issue number8
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Brachytherapy
Prostate
Radiation Oncology
Radiotherapy
Seeds
Iodine

Keywords

  • Brachytherapy
  • Predictive factors
  • Prostate cancer
  • Urinary toxicities

ASJC Scopus subject areas

  • Urology

Cite this

@article{ccc98bba667b49d68b17db82c16b2180,
title = "Predictive factors for acute and late urinary toxicity after permanent interstitial brachytherapy in Japanese patients",
abstract = "To describe the frequency of and to determine predictive factors associated with Radiation Therapy Oncology Group urinary toxicity in prostate brachytherapy patients. Methods: From January 2004 to April 2011, 466 consecutive Japanese patients underwent permanent iodine-125-seed brachytherapy (median follow up 48 months). International Prostate Symptom Score and Radiation Therapy Oncology Group toxicity data were prospectively collected. Prostate volume, International Prostate Symptom Score before and after brachytherapy, and postimplant analysis were examined for an association with urinary toxicity, defined as Radiation Therapy Oncology Group urinary toxicity of Grade1 or higher. Logistic regression analysis was used to examine the factors associated with urinary toxicity. Results: The rate of Radiation Therapy Oncology Group urinary toxicity grade1 or higher at 1, 6, 12, 24, 36 and 48 months was 67{\%}, 40{\%}, 21{\%}, 31{\%}, 27{\%} and 28{\%}, respectively. Grade2 or higher urinary toxicity was less than 1{\%} at each time-point. International Prostate Symptom Score was highest at 3 months and returned to normal 12 months after brachytherapy. On univariate analysis, patients with a larger prostate size, greater baseline International Prostate Symptom Score, higher prostate V100, higher prostate V150, higher prostate D90 and a greater number of seeds had more acute urinary toxicities at 1 month and 12 months after brachytherapy. On multivariate analysis, significant predictors for urinary toxicity at 1 month and 12 months were a greater baseline International Prostate Symptom Score and prostate V100. Conclusions: Most urinary symptoms are tolerated and resolved within 12 months after prostate brachytherapy. Acute and late urinary toxicity after brachytherapy is strongly related to the baseline International Prostate Symptom Score and prostate V100.",
keywords = "Brachytherapy, Predictive factors, Prostate cancer, Urinary toxicities",
author = "Ryuta Tanimoto and Kensuke Bekku and Norihisa Katayama and Yasuyuki Kobayashi and Shin Ebara and Motoo Araki and Mitsuhiro Takemoto and Hiroyuki Yanai and Yasutomo Nasu and Hiromi Kumon",
year = "2013",
month = "8",
doi = "10.1111/iju.12050",
language = "English",
volume = "20",
pages = "812--817",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Predictive factors for acute and late urinary toxicity after permanent interstitial brachytherapy in Japanese patients

AU - Tanimoto, Ryuta

AU - Bekku, Kensuke

AU - Katayama, Norihisa

AU - Kobayashi, Yasuyuki

AU - Ebara, Shin

AU - Araki, Motoo

AU - Takemoto, Mitsuhiro

AU - Yanai, Hiroyuki

AU - Nasu, Yasutomo

AU - Kumon, Hiromi

PY - 2013/8

Y1 - 2013/8

N2 - To describe the frequency of and to determine predictive factors associated with Radiation Therapy Oncology Group urinary toxicity in prostate brachytherapy patients. Methods: From January 2004 to April 2011, 466 consecutive Japanese patients underwent permanent iodine-125-seed brachytherapy (median follow up 48 months). International Prostate Symptom Score and Radiation Therapy Oncology Group toxicity data were prospectively collected. Prostate volume, International Prostate Symptom Score before and after brachytherapy, and postimplant analysis were examined for an association with urinary toxicity, defined as Radiation Therapy Oncology Group urinary toxicity of Grade1 or higher. Logistic regression analysis was used to examine the factors associated with urinary toxicity. Results: The rate of Radiation Therapy Oncology Group urinary toxicity grade1 or higher at 1, 6, 12, 24, 36 and 48 months was 67%, 40%, 21%, 31%, 27% and 28%, respectively. Grade2 or higher urinary toxicity was less than 1% at each time-point. International Prostate Symptom Score was highest at 3 months and returned to normal 12 months after brachytherapy. On univariate analysis, patients with a larger prostate size, greater baseline International Prostate Symptom Score, higher prostate V100, higher prostate V150, higher prostate D90 and a greater number of seeds had more acute urinary toxicities at 1 month and 12 months after brachytherapy. On multivariate analysis, significant predictors for urinary toxicity at 1 month and 12 months were a greater baseline International Prostate Symptom Score and prostate V100. Conclusions: Most urinary symptoms are tolerated and resolved within 12 months after prostate brachytherapy. Acute and late urinary toxicity after brachytherapy is strongly related to the baseline International Prostate Symptom Score and prostate V100.

AB - To describe the frequency of and to determine predictive factors associated with Radiation Therapy Oncology Group urinary toxicity in prostate brachytherapy patients. Methods: From January 2004 to April 2011, 466 consecutive Japanese patients underwent permanent iodine-125-seed brachytherapy (median follow up 48 months). International Prostate Symptom Score and Radiation Therapy Oncology Group toxicity data were prospectively collected. Prostate volume, International Prostate Symptom Score before and after brachytherapy, and postimplant analysis were examined for an association with urinary toxicity, defined as Radiation Therapy Oncology Group urinary toxicity of Grade1 or higher. Logistic regression analysis was used to examine the factors associated with urinary toxicity. Results: The rate of Radiation Therapy Oncology Group urinary toxicity grade1 or higher at 1, 6, 12, 24, 36 and 48 months was 67%, 40%, 21%, 31%, 27% and 28%, respectively. Grade2 or higher urinary toxicity was less than 1% at each time-point. International Prostate Symptom Score was highest at 3 months and returned to normal 12 months after brachytherapy. On univariate analysis, patients with a larger prostate size, greater baseline International Prostate Symptom Score, higher prostate V100, higher prostate V150, higher prostate D90 and a greater number of seeds had more acute urinary toxicities at 1 month and 12 months after brachytherapy. On multivariate analysis, significant predictors for urinary toxicity at 1 month and 12 months were a greater baseline International Prostate Symptom Score and prostate V100. Conclusions: Most urinary symptoms are tolerated and resolved within 12 months after prostate brachytherapy. Acute and late urinary toxicity after brachytherapy is strongly related to the baseline International Prostate Symptom Score and prostate V100.

KW - Brachytherapy

KW - Predictive factors

KW - Prostate cancer

KW - Urinary toxicities

UR - http://www.scopus.com/inward/record.url?scp=84881314302&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881314302&partnerID=8YFLogxK

U2 - 10.1111/iju.12050

DO - 10.1111/iju.12050

M3 - Article

VL - 20

SP - 812

EP - 817

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 8

ER -